Expression levels of pMEK1 and pAKT1 in CD138+ myeloma cells were associated with PFS in patients treated with SEL-based regimens. (A) Forest plot of PFS HRs for indicated marker expression in CD138+ cells from samples taken before SEL treatment at trial screening. HRs are not corrected for multiple testing. Kaplan-Meier curves showing PFS stratified by expression of pMEK1 S217/S221 (B) and pAKT1 S473 (C). (D) Volcano plot shows the differential expression of all assessed proteins for CD138+ MM cells between samples taken at screening and at time of PD after response. BRAF, B-Raf proto-oncogene, serine/threonine kinase; GZMB, granzyme B; HR, hazard ratio; ICOS, inducible T-cell costimulator; MET, MET proto-oncogene, receptor tyrosine kinase; PD-L2, programmed cell death 1 ligand 2; phospho-p90 RSK,phosphorylated p90 ribosomal protein S6 kinase A1; SMA, spinal muscular atrophy; PTEN, phosphatase and tensin homolog.
Figure 2.

Expression levels of pMEK1 and pAKT1 in CD138+ myeloma cells were associated with PFS in patients treated with SEL-based regimens. (A) Forest plot of PFS HRs for indicated marker expression in CD138+ cells from samples taken before SEL treatment at trial screening. HRs are not corrected for multiple testing. Kaplan-Meier curves showing PFS stratified by expression of pMEK1 S217/S221 (B) and pAKT1 S473 (C). (D) Volcano plot shows the differential expression of all assessed proteins for CD138+ MM cells between samples taken at screening and at time of PD after response. BRAF, B-Raf proto-oncogene, serine/threonine kinase; GZMB, granzyme B; HR, hazard ratio; ICOS, inducible T-cell costimulator; MET, MET proto-oncogene, receptor tyrosine kinase; PD-L2, programmed cell death 1 ligand 2; phospho-p90 RSK,phosphorylated p90 ribosomal protein S6 kinase A1; SMA, spinal muscular atrophy; PTEN, phosphatase and tensin homolog.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal